Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

November 30, 2025

Conditions
Neuroblastoma
Interventions
DRUG

Nivolumab

Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.

DRUG

Ch14.18/CHO

APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.

Trial Locations (3)

53792

University of Wisconsin Carbone Cancer Center; UW Hospital and Clinics; American Family Children's Hospital, Madison

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

NW1 2BU

University College London Hospital, London

All Listed Sponsors
collaborator

University College London Hospitals

OTHER

collaborator

University of Wisconsin, Madison

OTHER

collaborator

University Hospital Greifswald

OTHER

collaborator

Solving Kids' Cancer US/EU

UNKNOWN

collaborator

Joining Against Cancer in Kids

UNKNOWN

collaborator

The Band of Parents

UNKNOWN

lead

University Hospital Southampton NHS Foundation Trust

OTHER